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Abstract
Background: Breast cancer is uncommon in young women and induces more aggressive biologic characteristics.
Survival in young women has been widely studied in developed countries. Less favorable prognosis and low
survival were found.
In Morocco, this study is the first investigation of clinical features, treatment and prognosis associated with breast
cancer in young women.
Findings: Four hundred and nine women aged 35 years or less were included in this study. All these women were
diagnosed as having breast cancer at the National Institute of Oncology in Rabat, Morocco between 2003 and
2007. The relation between clinical and therapeutic characteristics and event-free survival (EFS) and overall survival
(OS) were assessed by Cox regression analysis.
The median age of the patients was 32 years. Fifty three patients (13%) have metastatic disease at diagnosis and
356 patients (87%) had localised disease. In 57.9% of the cases, the estrogen receptors status was positive. The
median follow-up was 32.2 months. After 3 years the survival rate was 80.6%. In the case of localised disease, OS
and EFS at 3 years were 83.2% and 62.5%, respectively. OS and EFS at 3 years was higher in patients with stage I
than patients with stage II and stage III (p = 0.001). Positive estrogen receptors was significantly associated to OS
and EFS at 3 years compared to negative estrogen receptors (p = 0.001). Adjuvant chemotherapy, adjuvant radio-
therapy and adjuvant hormone therapy were associated with net benefit in OS and EFS at 3 years. Cox regression
analysis showed that negative ER was significantly associated with poorer OS (HR = 2.42, 95% CI = 1.25 - 4.66,
p < 0.009) and poorer EFS (HR = 1.73, 95%CI = 1.05 - 2.86, p = 0.03). Stage III disease were associated to poorer
EFS (HR = 5.35, 95%CI = 1.60 -17.84, p = 0.006).
Conclusions: In Morocco, young women with breast cancer had less favorable prognosis. Multivariate analysis
showed that negative hormone receptor status was associated with lower EFS and OS. Clinical trials should be
launched to improve the survival of these young women with breast cancer.
Background
Breast cancer in young women is uncommon. Approxi-
mately 2% of patients with breast carcinoma are age ≤
35 years old at the time of diagnosis [1,2]. Information
is limited in this category of women. The definition of
“young women” varied from 30, 35, 40, 45, or even 50
years [3]. Young patients with breast cancer had more
aggressive clinical and biological characteristics, less
favorable outcome, and the disease was more linked to a
genetic predisposition compared with the disease in
older patients [4-7].
According to the 1998 St Gallen guidelines, age ≤ 35
was a poor prognostic factor and supported the use of
more aggressive systemic therapy, including che-
motherapy in all younger patients regardless of other
factors [8].
In addition, other particularities must be studied in
this category of patients: fertility, menopause induced by
treatment, self-image and sexuality.
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epidemiological, clinical and treatment characteristics in
young patients with breast cancer, and their relationship
with event free survival and overall survival.
Patients and methods
Clinical data
The National Institute of Oncology database was used to
identify patients with breast cancer aged 35 years or less
at the time of diagnosis between 2003 and 2007. We
excluded from the study patients who had not follow up
after initial diagnosis. The scientific comity of National
Institute of Oncology approved the retrospective review
of the medical records for the purposes of the current
study. Breast carcinoma diagnosis was made by biopsy of
the breast tumor. Tumor staging was carried out accord-
ing to the TNM classification 2002 modified in 2003.
Histological tumor grading was performed using the
Scarff Bloom and Richardson (SBR) histological system.
Immunohistochemical analysis to determine estrogen
(ER) and progesterone receptor (PR) status was per-
formed using standard procedures on 4-μms e c t i o n so f
paraffinembedded tissue specimens stained with the
monoclonal antibodies 6F11 and 1A6 for ER and PR,
respectively. Nuclear staining 10% was considered a
positive result.
Patients were considered HER2-positive if they had
immunohistochemistry (IHC) 3+ by DAKO HercepTest.
Fluorescence in situ hybridization was used when IHC
was 2+ and it was considered positive if we have ≥ two-
fold amplification; confirmed by central testing. The
hercept test was realized in the institute from 2004.
Treatment
Patients how had metastatic disease at diagnosis
received chemotherapy or hormonotherapy based on the
characteristics of the tumors and the aggressiveness of
the disease. This patients can receive palliative radio-
therapy if indication. Patients with local disease had
received corresponding local treatments (surgery plus
radiotherapy) and systemic treatments (mainly adjuvant
and/or neoadjuvante chemotherapy and endocrine ther-
apy). The main surgical operations included radical mas-
tectomy (Patey type mastectomy) and breast conserving
surgery when permitted by tumor size according to the
judgment of the multidisciplinary care team.
In our institute, adjuvant chemotherapy is indicated in
the case of tumor size greater than or equal to 2 cm,
positive nodal status, grade 2 or 3 SBR, amplification of
HER 2 and age ≤ 35 years. Neoadjuvante chemotherapy
was giving in patients with inflammatory or locally
advanced breast cancer. For the patients who did not
receive adjuvant chemotherapy, they have received
neoadjuvante chemotherapy or they did not return after
surgery for personal reasons.
For patients receiving neoadjuvante chemotherapy, a
pathologic complete response was defined as no evi-
dence of invasive carcinoma in the breast and the axil-
lary lymph nodes at the time of surgery. Chevalier
classification was used to classify histological response
to neoadjuvante chemotherapy in the breast [9].
Anthracycline containing regimens were mainly used
for adjuvant and/or neoadjuvante chemotherapy (FEC
100 protocol with Fluorouracil 500 mg/m
2,E p i r u b i c i n
100 mg/m
2 IV, Cyclophosphamide 500 mg/m
2 and
AC60 protocol with Doxorubicin 60 mg/m
2,C y c l o p h o -
sphamide 600 mg/m
2) while CMF regimen (Cyclopho-
sphamide 600 mg/m
2, Metotrexate 40 mg/m
2,
Fluorouracil: 500 mg/m
2) was administrated instead in
some minor cases. Docetaxel was administered at a dose
of 100 mg/m
2 when used in monotherapy and at a dose
of 75 mg/m
2 in combination with anthracyclin. The
choice of chemotherapy protocols depended on the
availability of products at the time of the indication.
Patients with hormone receptor positive tumor speci-
mens received tamoxifen at a dose of 20 mg daily for
5 years. Adjuvant radiotherapy was indicated the case of
tumor size greater than 5 cm, invasion of the pectoral
fascia, more than four metastatic axillary lymph nodes,
positive surgical margin and breast conservation.
Follow up
Patients were followed up until January 2010. All
patients who are not reviewed in the last consultation
were contacted again by telephone. Locoregional recur-
rence meant the recurrence in ipsilateral mammary
glands, chest wall, or regional lymph nodes identified
clinically or histologically, while distant metastasis
referred to the metastatic carcinoma detected by clinical
examination or imaging. Event free survival (EFS) was
calculated from the date of surgery or the first course of
neoadjuvante chemotherapy to the date of event (loco
regional or metastatic relapse, or death) or last follow
up. Patients with stage IV disease at diagnosis were
excluded from the statistical evaluation of EFS. Overall
survival (OS) was calculated from the date of diagnosis
(fin needles aspiration, biopsies or radical mastectomy)
to the date of death or last follow-up.
Statistical analysis
SPSS13.0 software was used for statistical analysis.
Descriptive of clinical data were expressed in percentage
or median or mean ± SD. Survival was estimated by the
Kaplan Meier method, and compared by the log rank
test. The relationship between each of the explanatory
variables and outcome (EFS and OS) was assessed in
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analysis. A p value of < 0.05 was considered significant.
Consent and statement of ethical approval
As the treatment of each patient was decided by the
medical staff of the centre, oral consent was obtained
from the subjects and was approved by the institutional
review boards of the National Institute of Oncology,
Cancer Centre in Rabat. This study was approved by the
institutional review boards of National Institute of
Oncology, in Rabat.
Results
Clinical characteristics of all patients
Four hundred and twenty seven patients aged 35 years
or younger were diagnosed with breast cancer between
January 2003 and December 2007. Four hundred and
nine patients were included. The median follow-up time
w a s3 2 . 2m o n t h s( r a n g e2 -8 4 . 8m o n t h s ) .T a b l e1s u m -
marizes patient characteristics. The median age at diag-
nosis was 32 years (range 15-35 years). Twenty-eight
patients (6.8%) had a family history of breast cancer.
BRCA mutation was sought in only a single case and
was present. One hundred and twenty one patients
(59%) had nursing antecedents and 129 patients (31.5%)
reported use of oral contraceptives. Three hundred and
sixty patients (88.2%) had infiltrating ductal carcinoma.
Two hundred and six cases (50.4%) were grade II Scarff-
Bloom-Richardson (SBR), 53.8% of the cases were
estrogen receptors positive, and 61.6% of the cases were
progesterone receptors positive. The Her2 status gene
amplification was performed in 57 patients. HER-2 was
positive in only 28 patients. Fifty three patients (13%)
had metastatic disease (stage IV) at first diagnosis, 30
patients (7.3%) had stage I, 140 patients (34.2%) had
stage II and the remaining 186 patients (45.5%) had
stage III.
Treatment and outcome
All patients
Three hundred and fifty six patients (87%) had local dis-
ease at diagnosis and 53 patients (13%) had metastatic
disease. At the end of the study period, 92 patients
(22.49%) died. For all patients, survival at 3 years was
80.6%. Overall survival rate at 3 years was 100%, 89.3%,
74.7%, and 57.8% in stage I, stage II, stage III and stage
IV respectively. This difference was statistically signifi-
cant: Log rank test, p < 0.001 (figure 1).
Metastatic disease
Among 53 patients with metastatic disease, 18 patients
(34%) received surgical treatment. Forty seven patients
(88.7%) received anthracycline-based regimen in the first
line metastatic chemotherapy: thirty-seven patients
(78.7%) received AC 60 protocol, six patients (12.8%)
Table 1 Clinical characteristics of all Patients
Characteristics No. of patients (%)
Nursing 121 59
Family history of breast carcinoma
Yes 28 6.8
No 254 62.1
Unknown 127 31.1
SBR grading
I 17 4.1
II 206 50.4
III 155 37.9
Unknown 31 7.6
Estrogen receptor
positive 220 53.8
negative 160 39.1
Unknown 29 7.1
Progesterone receptor
Positive 252 61.6
negative 128 31.3
Unknown 29 7.1
M stage
M0 356 87
M1 53 13
TNM Stage
Stage I 30 7.3
Stage II 140 34.2
Stage III 186 45.5
Stage IV 53 13
HER2
Positive 28 6.8
negative 29 7.1
unknown 352 86.1 Figure 1 Survival for all patients according to TNM stage.
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received AT protocol. Trastuzumab was not prescribed
for any patients with Her 2 positive status (Table 2).
No significant difference in OS at 3 years was seen
between the 2 groups of patients how received che-
motherapy or not received chemotherapy (57.7% vs 50%
respectively; Log rank test: p = 0.4) (Table 2).
Non metastatic disease
From three hundred and fifty six patients how had loca-
lized disease, 186 patients (52.2%) had stage III at diag-
nosis, 140 patients (39.3%) with stage II and 30 patients
(8.4%) with stage I (table 3). Positive estrogen receptors
status was significantly associated with OS and EFS at
3 years compared to negative estrogen receptors status
(p = 0.001). Three hundred and forty seven patients
(97.5%) received surgery in which 80 patients (23.2%)
had conservative surgery (tumorectomy with axillary
lymph nodes). The remaining patients 76.8% received
radical mastectomy with axillary lymph nodes dissection
(Patey type mastectomy) (table 3). All patients with local
disease, who were operated, received optimal surgery
with free histological margins. Patients with advanced
tumors or inflammatory breast cancer have received
neoadjuvante chemotherapy before surgery. No signifi-
cant difference in OS and EFS at 3 years was seen in
patients how had radical or conserving surgery.(Table 4).
Seventy six patients (21.3%) received neoadjuvante che-
motherapy wich 69 patients (90.8%) had Anthracycline
based chemotherapy (AC60, FAC50 and FEC100), five
patients (6.6%) received CMFp r o t o c o la n dt w op a t i e n t s
(2.6%) had Anthracycline and taxane protocol (3 cycles of
AC60 folowed by 3 cycles of docetaxel). Only two
patients had complete response to neoadjuvante
chemotherapy. Most patients had a chevalier response 3
and 4 (50 and 39.5% respectively) (table 3).
From 311 patients how received adjuvant chemother-
apy, 273 patients (87.8%) had Anthracycline based che-
motherapy (AC60, FAC50 and FEC100), 13 patients
(4.2%) had sequential Anthracycline and docetaxel, 14
patients (4.5%) received CMF protocol and 11 patients
(3.5%) had docetaxel as adjuvant chemotherapy (table
3). Fifty five patients received previous neoadjuvante
chemotherapy.
OS and EFS at 3 years were higher in patients how
received adjuvant chemotherapy. (Table 5) Twenty-four
patients had HER 2 positive and none of them has
received trastuzumab (table 3).
According to standard recommendations for localised
breast cancer when lymph nodes were affected, 290
patients (81.5%) received adjuvant radiotherapy (table3).
OS and EFS at 3 years were higher in patients how
received adjuvant radiotherapy compared to patients
how not received adjuvant radiotherapy. The difference
was statistically significant (table 4). From 232 patients
how had hormone therapy, 230 patients (64.6%) received
tamoxifen in adjuvant setting in the case of positive hor-
mone receptors status and two patients received castra-
tion (table 3). OS and EFS at 3 years was statistically
significant for patients how received hormone therapy
(85.9 vs 76.6%; p = 0,001 and 69.5 vs 48%; p = 0,001
respectively).
At last follow up, forty four patients (12.4%) experi-
enced local relapse, ninety two patients (25.8%) had
metastatic progression and s i x t yn i n ep a t i e n t s( 1 9 . 4 % )
died. For all patients with localised disease, OS and EFS
at 3 years were 83.2 and 62.5% respectively.
Table 2 Treatment characteristics and overall survival in patients with metastatic disease
No. of patients(%) 3-Year OS(%) Median OS p
Months 95%CI
Surgery
Yes 18 (34) - - - -
No 35 (66) - - -
Metastatic First line Chemotherapy
No chemotherapy 6 (11.3) 50 20.2 0 – 40.4 0.40
Chemotherapy 47 (88.7) 57.7 39 30.6 – 47.3
Chemotherapy protocol
AC 60 37 (78.7) 57.7 41.4 21.6 – 61.2 0.65
FEC 100 6 (12.8) 33.3 35.1 30.4 – 39.8
AT 4 (8.5) NR 39 NR
Hormonotherapy
No hormonotherapy 41 (77.4) 58.3 39 27.1 -50.8 0.60
hormonotherapy 12 (22.6) 48.4 35.1 5.5 – 64.8
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Factors influencing survival Univariate analysis showed
that the factors significantly influencing OS were the
negative ER status, advanced tumoral stage, absence of
adjuvant chemotherapy and adjuvant endocrine therapy
for patients with positive ER, and absence of adjuvant
radiotherapy (table 5). Multivariate analysis showed that
only negative ER was significantly associated with poorer
overall survival. (HR = 2.54, 95% CI = 1.32- 4.90, p <
0.005) (table 5).
Table 3 Treatments and Disease characteristics in
patients with local disease
Characteristic No. of patients (%)
No. of patients 356 100
Tumor size
T1 48 13.5
T2 161 45.2
T3 71 19.9
T4 76 21.3
N Statut
N0 107 30.1
N1 74 20.8
N2 93 26.1
N3 82 23
HER 2
HER 2 negative 23 48.9
HER 2 positive 24 51.1
TNM
Stage I 30 8.4
Stage II 140 39.3
Stage III 186 52.2
Surgery
Yes 347 97.5
No 9 2.5
Surgery type
Radical mastectomy 265 76.8
Concerving surgery 80 23.2
Radiotherapy
Yes 290 81.5
No 66 18.5
Neoadjuvante chemotherapy
Yes 76 21.3
No 280 78.7
Neoadjuvante chemotherapy type
Anthracycline 69 90.8
CMF 5 6.6
AC60/TAXANE 2 2.6
Histological response to neoadjuvante chemotherapy
Chevalier 1 2 2.6
Chevalier 2 6 7.9
Chevalier 3 38 50
Chevalier 4 30 39.5
Adjuvant chemotherapy
Yes 311 87.4
No 45 12.6
Adjuvant hormonotherapy
Yes 232 64.6
No 124 35.4
Table 4 OS and EFS in patients35 years and younger
with local breast cancer
No. of
patients
3-Year OS
(%)
P 3-Year EFS
(%)
P
Stage I-III 356 83.2 - 62.5 -
Tumor size
T1 48 89.3 0.76 75.9 0.32
T2 161 85.5 65
T3 71 79.5 56
T4 76 77.5 55.2
SBR grading
SBR I 14 100 0.20 67.5 0.45
SBR II 176 84.9 63.2
SBR III 137 78 58.8
ER
ER positive 179 94.4 0.001 75.8 0.001
ER negative 149 70.2 50.6
N stage
N0 107 79.4 0.32 59.8 0.20
N+ 249 84.8 63.6
Surgery type
Radical
mastectomy
265 82.3 0.17 61.9 0.059
Conserving
surgery
80 87.7 70.4
Adjuvant radiotherapy
Yes 290 85.2 0.002 65.7 0.001
No 66 70.2 48.6
Adjuvant chemotherapy
No 45 65.4 0.04 44.7 0.001
Yes 311 85 64.9
Hormonotherapy
Yes 232 85.9 0.001 69.5 0.001
No 124 76.6 48
Stage
I 30 100 0.001 93 0.001
II 140 89.4 76.3
III 186 74.7 46.8
ER. estrogen receptors; N. lymph node; CI. confidence interval; OS. overall
survival; EFS. event free survival.
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lysis indicated that advanced tumoral stage, negative
ER, absence of adjuvant chemotherapy, radiotherapy,
and hormone therapy, and conservative surgery were
all risk factors of poorer event free survival (table 6),
however multivariate analysis showed that negative ER
status and advanced stage III disease were the only
factors associated with poorer event free survival
(table 6).
Discussion
This work conducted at the national institute of oncol-
ogy in morocco analyzed the epidemiological, clinical,
therapeutic and prognostic characteristics of breast can-
cer in women aged 35 years or less and the relationship
between these characteristics and outcome (EFS and
OS).
Of 5309 patients diagnosed with breast cancer
between 2003 and 2007, 8% of the cases were aged 35
Table 5 Cox Proportional Hazards Model of Overall Survival for patients with local disease
Univariate analysis Multivariate analysis
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Family history
No 1.00 1.00
Yes 1.10 0.47 – 2.58 0.83 1.12 0.44–2.88 0.81
SBR grading
SBR I 1.00 1.00
SBR II 2.01 0.27 – 14.6 0.49 1.26 0.15–10.9 0.83
SBR III 2.55 0.35 – 18.69 0.36 1.03 0.12–8.76 0.97
Tumor size
T1 1.00 1.00
T2 1.54 0.65 – 3.66 0.33 2.25 0.50–10.19 0.30
T3 1.55 0.59 – 4.1 0.38 2.50 0.47–13.42 0.29
T4 1.64 0.64 – 4.23 0. 31 2.34 0.44–12.44 0.32
N statut
N– 1.00 1.00
N+ 0.78 0.47 – 1.28 0.32 0.62 0.29–1.30 0.20
Stage
I 1.00 1.00
II 2.10 0.53 – 8.37 0.29 1.43 0.24–8.57 0.69
III 4.24 1.1 – 16.28 0.03 3.56 0.65–19.57 0.14
ER
ER positive 1.00 1.00
ER negative 2.25 1.37 – 3.72 0.001 2.54 1.32–4.90 0.005
Adjuvant chemotherapy
No 1.00 1.00
Yes 0.49 0.24 – 0.99 0.04 0.74 0.18–3.05 0.68
Adjuvant hormonotherapy
No 1.00 1.00
Yes 0.45 0.28 – 0.73 0.001 0.89 0.45–1.77 0.74
Surgery type
Radical mastectomy 1.00 1.00
Conserving surgery 0.64 0. 34 – 1.23 0.17 0.50 0.19–1.18 0.11
Adjuvant radiotherapy
No 1.00 1.00
Yes 0.42 0.24–0.74 0.003 0.74 0.25–2.23 0.60
1. Reference; ER. estrogen receptors; N. lymph node; CI. confidence interval; OS. overall survival; EFS. Events free survival.
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could be partially attributed to the higher proportion of
young women in the general population. In the US, the
women aged 35 years or younger represent only 2.7% of
new cases [10]. In Asian series, this number varies
between 10% in developed and up to 24% in developing
countries [11].
This study found less than 10% of family history of
breast cancer and no evidence for a relationship
between family history of breast cancer and survival.
However, family history of breast cancer is an important
indicator of risk in young women. In a Swedish popula-
tion-based study of 262 women with breast cancer aged
40 years or younger, 48% of patients had a family his-
tory of breast or ovarian cancer [12].
The reports studied the impact of age and others
prognostic factors showed that high tumor grade repre-
sents an individual prognostic factor in younger and
older premenopausal patients [13]. In addition, several
studies published after 1995 reported that the unfavor-
able impact of young age on survival was present only
in patients who did not receive chemotherapy [14].
Table 6 Cox Proportional Hazards Model of Event free survival for patients with local disease
Univariate analysis Multivariate analysis
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Family history
No 1.00 1.00
Yes 1.25 0.66 – 2.34 0.49 0.86 0.41–1.84 0.71
SBR grading
SBR I 1.00 1.00
SBR II 0.66 0.26 – 1.64 0.36 0.62 0.17–2.25 0.47
SBR III 0.79 0.32 – 1.99 0.63 0.69 1.19–2.47 0.57
Tumor size
T1 1.00 1.00
T2 1.26 0.69 – 2.30 0.45 1.27 0.51–3.17 0.61
T3 1.68 0.87 – 3.23 0.12 1.10 0.35–3.14 0.93
T4 1.56 0.82 – 2.98 0.17 1.40 0.48–3.81 0.57
N statut
N– 1.00 1.00
N+ 0.79 0.55 – 1.13 0.20 0.74 0.42–1.30 0.29
Stage
I 1.00 1.00
II 4.33 1.04 – 17.9 0.04 2.03 0.57 – 7.25 0.27
III 10.96 2.70 – 44.5 0.01 5.35 1.60–17.84 0.01
ER
ER positive 1.00 1.00
ER negative 1.83 1.26 – 2.64 0.01 1.63 1.00 – 2.67 0.05
Adjuvant chemotherapy
No 1.00 1.00
Yes 0.45 0.28 – 0.73 0.001 0.90 0.33 –2.52 0.85
Adjuvant hormonotherapy
No 1.00 1.00
Yes 0.43 0.30 – 0.60 0.001 0.73 0.43 –1.23 0.24
Surgery type
Radical mastectomy 1.00 1.00
Conserving surgery 0.63 0.40 – 1.01 0.05 0.74 0.42 –1.13 0.30
Adjuvant radiotherapy
No 1.00 1.00
Yes 0.45 0.30 – 0.68 0.001 0.82 0.35–1.19 0.64
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showed that the outcome of patients aged ≤ 35 years
was less favorable than those aged > 35 years. In fact,
the outcome of young women with localized disease
included in the present study is less favorable than that
of patients having localized disease followed in the same
Institute and included in a previous study [17]. Also, in
this work, we found that women were more likely to
receive adjuvant chemotherapy and they had a better
survival, however high tumor grade was not influenced
survival.
Our findings revealed that negative ER status was
associated with lower survival and event free survival in
univariate and multivariate analysis. Curigliano [18] and
Aebi [19] noted that the positive ER status in young
patients seems to have a different prognostic value. Data
suggest that very young women with endocrine-respon-
sive tumors had a statistically significant higher risk of
disease recurrence than older premenopausal patients.
In contrast, results in younger and older premenopausal
patients were similar in the case of the ER positive sta-
tus. However, Ana M. Gonzalez-Angulo[20] et all found
that Hormone receptor negativity was associated with
shorter RFS and OS. This result was consistent with our
finding.
Breast cancer in young women is frequently diagnosed
at advanced stage [21]. Consequently, the majority of
patients received radical mastectomy. In addition, a
positive family history or the presence of a BRCA1/2
gene mutation will also influence decisions for mastect-
omy rather than breast conservation [3]. Until now,
there is still no final conclusion about whether age is a
risk factor of local recurrence in breast conserved cases,
and there are still inconsistent findings in previous clini-
cal studies. But it was reported in most studies that
among those who received breast conserving surgery,
young patients had a higher local recurrence rate.
[22-28] Over 20% of our patients with local disease
received conservative surgery. These patients had lower
event-free survival than patients who received radical
mastectomy. The difference tended towards significance.
The updated Early Breast Cancer Clinical Trialists’
meta-analysis have shown beneficial effects of adjuvant
tamoxifen in younger women [29], as well as the find-
ings from the International Breast Cancer Study Group
(Trial 13-93) [30]. In our series, the patients with loca-
lised disease and estrogen receptor positive status, how
had received the hormonal treatment had better OS and
EFS.
However our retrospective study showed several lim-
itations because it implicated potential bias in the choice
of treatment. In addition, the lake of cytogenetic investi-
gation of BRCA gene mutation due to the low socio-
economic level of these patients and the lake of Her-2
gene amplification test in the majority of our patients
are 2 major limitations.
Conclusion
In Morocco, the incidence of breast cancer in young
women aged ≤ 35 is higher compared than that in
developed countries. In thiss u b g r o u po fp a t i e n t s ,t h e
invasive breast cancer has more aggressive behaviors. In
addition, the ER negative status was associated with
lower EFS and OS. Further research program and clini-
cal trials were needed in young Moroccan breast cancer
women improve their management and their outcome.
List of abriviations
CI: Confidence interval; ER: Estrogen receptor; EFS: Event free survival; HR:
Hazard ratio; IHC: Immunohistochemistry; N: lymph nodes; OS: Overall
surviaval; SD: Standard deviation.
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